Stifel Maintains Buy on Immunovant, Raises Price Target to $34
Portfolio Pulse from richadhand@benzinga.com
Stifel analyst Alex Thompson maintains a 'Buy' rating on Immunovant (NASDAQ:IMVT) and raises the price target from $28 to $34.
July 18, 2023 | 12:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel analyst Alex Thompson maintains a 'Buy' rating on Immunovant and raises the price target from $28 to $34.
The raised price target by Stifel indicates a positive outlook for Immunovant. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100